479M-9
MDM2 (IF2) Mouse Monoclonal Antibody
别名:
Mouse double minute protein 2
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
IF2, monoclonal
Application:
IHC (p)
Citations:
8
biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
IF2, monoclonal
description
For In Vitro Diagnostic Use in Select Regions
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (479M-94), vial of 0.1 mL concentrate Research Use Only (479M-94-RUO), vial of 0.5 mL concentrate (479M-95), vial of 1.0 mL concentrate (479M-96), vial of 1.0 mL concentrate Research Use Only (479M-96-RUO), vial of 1.0 mL pre-dilute Research Use Only (479M-97-RUO), vial of 1.0 mL pre-dilute ready-to-use (479M-97), vial of 7.0 mL pre-dilute ready-to-use (479M-98), vial of 7.0 mL pre-dilute ready-to-use Research Use Only (479M-98-RUO)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:50 (concentrated)
isotype
IgG
control
dedifferentiated liposarcoma, well-differentiated liposarcoma
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
General description
Mouse double minute protein 2 (MDM2) is a gene encoded on the 12q13-14 chromosomal sequence.1-5 It encodes for a 483 amino acid residue protein which binds to the amino-terminal transcription region of p53.2,5 MDM2 has been shown to negatively regulate the tumor-suppressor activity of p53 by three mechanisms: Blocking p53 transcription, binding to p53 causing it to be exported from the nucleus, and accelerating the destruction of p53.1 MDM2 up-regulation has been shown in liposarcoma while being absent in lipoma.2,4 Therefore, anti-MDM2 has been demonstrated to be a potentially useful tool in distinguishing well-differentiated liposarcoma (atypical lipomatous tumor) from lipoma, with the neoplastic cells positive in the former lesion and negative in lipoma.2,4
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.
Preparation Note
Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.
Download the latest released IFU
Note: This IFU may not apply to your specific product lot.
Note: This requires a keycode which can be found on your packaging or product label.
Download the latest released IFU
Note: This IFU may not apply to your specific product lot.
Analysis Note
United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO
Canada - RUO
European Union - IVD
Japan - RUO
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
法规信息
监管及禁止进口产品
此项目有
Stanislava Uhrinova et al.
Journal of molecular biology, 350(3), 587-598 (2005-06-15)
Critical to the inhibitory action of the oncogene product, MDM2, on the tumour suppressor, p53, is association of the N-terminal domain of MDM2 (MDM2N) with the transactivation domain of p53. The structure of MDM2N was previously solved with a p53-derived
Patrick L Ware et al.
American journal of clinical pathology, 141(3), 334-341 (2014-02-12)
MDM2 gene amplification is associated with well-differentiated (WDL) and dedifferentiated liposarcomas (DDL). Using fluorescent in situ hybridization (FISH), we sought to characterize various patterns of MDM2 amplification among the morphologic spectrum of liposarcoma. Forty-six cases of liposarcoma in various sites
Matthieu Bui Nguyen Binh et al.
American journal of clinical pathology, 125(5), 693-697 (2006-05-19)
MDM2 and CDK4 immunostaining can be useful adjuncts in diagnosing liposarcoma among soft tissue neoplasms. We examined the reproducibility of MDM2 and CDK4 staining between 2 laboratories and between tissue microarrays and whole tissue sections. Sixty-two soft tissue tumors were
J Momand et al.
Nucleic acids research, 26(15), 3453-3459 (1998-07-22)
The p53 tumor suppressor gene is inactivated in human tumors by several distinct mechanisms. The best characterized inactivation mechanisms are: (i) gene mutation; (ii) p53 protein association with viral proteins; (iii) p53 protein association with the MDM2 cellular oncoprotein. The
Matthieu Bui Nguyen Binh et al.
The American journal of surgical pathology, 29(10), 1340-1347 (2005-09-15)
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) may be difficult to distinguish from benign adipose tumors and from poorly differentiated sarcomas, respectively. Genetically, they are characterized by amplification of MDM2 and CDK4 genes on chromosome 12q13-15. We examined
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持